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Abstract
Background: The aim of our study was to examine regional differences in the demographics, 
etiology, risk factors, comorbidities and treatment of female patients with heart failure (HF) in 
the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD) clinical trial.
Methods and results: One hundred and fifty-nine female patients from Germany and 169 
from Southeastern (SE) Europe (Serbia, Slovenia and Montenegro) were included in this sub-
analysis of the CIBIS-ELD trial. Women comprised 54% of the study population in Germany 
and 29% in SE Europe. German patients were significantly older. The leading cause of HF was 
arterial hypertension in German patients, 71.7% of whom had a preserved ejection fraction. 
The leading etiology in SE Europe was the coronary artery disease; 67.6% of these patients had 
a reduced left ventricular ejection fraction (34.64 ± 7.75%). No significant differences were fo-
und in the prevalence of traditional cardiovascular risk factors between the two regions (hyper-
tension, diabetes, hypercholesterolemia, smoking and family history of myocardial infarction). 
Depression, chronic obstructive pulmonary disease and malignancies were the comorbidities 
that were noted more frequently in the German patients, while the patients from SE Europe 
had a lower glomerular filtration rate. Compared with the German HF patients, the females in 
SE Europe received significantly more angiotensin converting enzyme inhibitors, loop diuretics 
and less frequently angiotensin receptor blockers and mineralocorticoid receptor antagonists.
Conclusions: Significant regional differences were noted in the etiology, comorbidities and 
treatment of female patients with HF despite similar risk factors. Such differences should be 
considered in the design and implementation of future clinical trials, especially as women 
remain underrepresented in large trial populations. (Cardiol J 2014; 21, 3: 265–272)
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Introduction
Cardiovascular diseases are the main cause of 
mortality in the European Union, accounting for 
near 40% of deaths in the total population. Around 
1–2% of the population in European countries 
suffers from heart failure (HF), with the preva-
lence rising to ≥ 10% among the population aged 
≥ 70 years [1].
Underrepresentation of women in cardiova-
scular trials has been clearly demonstrated in the 
past. Since 2006, 11 randomized trials of HF have 
included 46,141 patients, 12,834 of whom were 
women (27.8%, range 15–60%).
In Europe women have a longer life expec-
tancy with marked differences among different 
countries. This gender gap in life expectancy, fa-
voring women, shows a threefold variation among 
the countries [2].
The past decade has seen a trend toward the 
globalization of clinical trials with greater partici-
pation of the emerging countries [3]. The balance 
among the regions represented in the trial is 
important in order to avoid over-representation 
and possible interpretation bias. Despite relati-
vely strict inclusion and exclusion criteria in HF 
trials, patient populations remained heterogeneous 
among the regions in terms of baseline characteri-
stics, treatment and outcomes. However, regional 
differences should not discourage the globalization 
of clinical trials; it is interesting to note that sub-
group analyses based on geographical regions have 
rarely changed the main results of HF trials [4, 5].
Although women comprise 40% of the HF 
population, they are underrepresented in clinical 
trials [6]. Cardiovascular diseases are the leading 
cause of death in Europe among women, propor-
tionally more than among men (54% vs. 43%). 
However, this is not reflected in current HF regi-
stries, which have a predominately male population 
from Western European countries. Furthermore, 
current guidelines do not include gender-related 
management recommendations.
Little is known about gender-related differen-
ces in HF patients in terms of clinical characteri-
stics, echocardiographic measures and outcomes. 
Women more frequently have HF with preserved 
left ventricular (LV) function. They are also signi-
ficantly older than male HF patients, probably due 
to the later onset of HF [7, 8].
The multinational, multicenter, prospective, 
randomized Cardiac Insufficiency BIsoprolol Study 
in ELDerly (CIBIS-ELD) study, which compared the 
short-term titration of bisoprolol and carvedilol in 
HF patients, lends itself particularly to the explo-
ration of basic regional differences in an underre-
presented population — elderly female patients 
with chronic HF from Germany and Southeastern 
(SE) Europe.
The aim of our study was to compare female 
populations with chronic HF from these two dif-
ferent regions focusing on the differences which 
could influence the design of future clinical trials 
and ultimately to the guidelines development.
Methods
CIBIS ELD is a double-blind superiority trial 
comparing the titration of bisoprolol vs. carvedilol 
in elderly patients suffering from HF with the 
reduced ejection fraction (HFrEF) or HF with 
preserved ejection fraction (HFpEF). Patients 
were 65 years old or older with the symptomatic 
chronic HF consistent with New York Heart Asso-
ciation (NYHA) functional class ≥ II at the time of 
inclusion or with LVEF £ 45%. At the beginning 
of the study, participants had to be beta-blocker 
naïve or on £ 25% of the guideline-recommended 
target or equivalent dose. The study participants 
had to be clinically stable and on stable medication 
for 2 weeks prior to randomization. Major exclu-
sion criteria were: known contraindications to 
beta-blocker treatment, such as hypotension with 
a resting systolic blood pressure < 90 mm Hg, 
severe pulmonary disease or severe asthma, heart 
rate < 55/min prior to the commencement of the 
therapy, the second or third degree sinoatrial block 
(without pacemaker), and diagnosed sick sinus syn-
drome. Tolerability, defined as achieving guideline-
-recommended beta-blocker doses after 12 weeks, 
was assessed as the primary endpoint [9].
In this analysis based on the CIBIS-ELD study 
population we included 159 patients from Germany 
(54% of all the included patients from Germany) 
and 169 patients from SE Europe (29% of all the 
included patients from SE Europe). Female patients 
from Germany and SE Europe had different profiles 
of cardiovascular characteristics, co-morbidities, 
and risk factors.
Baseline variables were presented as frequen-
cies and percentages for binary variables or means 
and standard deviations for quantitative variables. 
Comparisons of the groups were performed by 
the c2 test or analysis of variance, respectively. 
P < 0.05 was considered statistically significant. 
SPSS version 17 was used as statistical software.
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Results
General characteristics
Baseline characteristics are presented in Table 1. 
Women from Germany were significantly older, 
with a shorter duration of HF. There was a signifi-
cant difference in HF etiology observed between 
the two regions. HFpEF was the most common 
type in women from Germany (71.7%) compared to 
HFrEF in women from SE Europe (67.6%). In SE 
European patients with HFrEF the average LVEF 
was 34.64 ± 7.75%, while in the same subgroup 
of German female patients it was 35.74 ± 8.72%.
In the majority of patients dyspnea was repor-
ted on mild exertion (NYHA class II) (Fig. 1). How-
ever, there were significant differences in NYHA 
class distribution between the observed groups 
(c2 = 10.89, p < 0.05). The patients in SE Europe 
were generally more symptomatic than the German 
patients. Similarly, female patients from SE Europe 
had significantly higher N-terminal prohormone of 
B-type natriuretic peptide (NT-proBNP) levels at 
the beginning and at the end of the study (Table 1).
Risk factors
There were no significant differences in smo-
king habits (Fig. 2). Hyperlipidemia was similarly 
distributed in both regions (prevalence in Germany 
67.9% vs. SE Europe 63.9%, p = 0.485; chole-
sterol level 5.54 ± 1.23 vs. 5.76 ± 1.56 mmol/L, 
p = 0.167). There were no significant differences 
in percentages of reported family history of fatal 
myocardial infarction (MI) before the age of 60 
years (Germany and SE Europe: 20.1% vs. 15.4%, 
p = 0.164).
Table 1. Baseline patients’ characteristics.
Patients’ characteristics Female patients 
from Germany
Female patients  
from SE Europe
P
Age [years] 74.13±6.16 72.20±4.84 < 0.01
Duration of HF [years] 1.49 ± 3.88 5.47 ± 6.17 < 0.001
Etiology of HF AH: 65.2% CAD: 46.3% < 0.001
History of angina pectoris and MI 35.5%/15.1% 82.6%/17.4% < 0.001/ 
/< 0.001
HFpEF 71.7% 32.4% < 0.001
Atrial fibrillation 6.9% 16.6% < 0.01
Pacemaker rhythm 3.1% 1.8% < 0.05
Baseline NT-proBNP levels [pg/mL] 645.5 ± 1163.1 1560.5 ± 2242.9 < 0.001
Post-treatment NT-proBNP levels  
at the end of study [pg/mL]
673.8 ± 1162.04 1145.3 ± 469.5 < 0.01
Left ventricular ejection fraction 51.57 ± 14.8% 36.68 ± 9.6 % < 0.001
AH — arterial hypertension; CAD — coronary artery disease; HF — heart failure; HFpEF — heart failure with preserved ejection fraction; MI — 
myocardial infarction; NT-proBNP — N-terminal prohormone of B-type natriuretic peptide; SE — Southeastern
Figure 1. Distribution of functional New York Heart As-
sociation classes in patients from Germany and Southe-
astern Europe.
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No difference was observed in the prevalence 
of arterial hypertension (Germany vs. SE Europe: 
86.8% vs. 88.2%, p = 0.741), however there were 
significant differences in its severity. Women 
from SE Europe more commonly had mild hyper-
tension (stage 2 according to ESC guidelines) in 
comparison to those from Germany, where stages 
3 and 4 were more frequently observed (c2 = 13.5, 
p < 0.01) [10].
Women from Germany were more commonly 
obese than those from SE Europe (body mass in-
dex [BMI]: 30.3 ± 6.5 vs. 27.7 ± 4.9, F = 16.675, 
p < 0.001).
Alcohol consumption was different between 
the observed groups: c2 = 29.86, p < 0.01. Only 
10.7% of the SE European patients reported alcohol 
consumption compared to 29.1% of the German 
patients. The majority of the German patients 
consumed only 1 drink per week defined as 0.25 L 
of beer or 0.1 L of wine or 2 cl liquor.
Hyperuricemia was more prevalent among the 
patients from Germany: 15.1% vs. 2.4%, c2 = 16.99, 
p < 0.001.
Comorbidities
No significant differences were observed in the 
prevalence of diabetes, cerebrovascular morbidity, 
anemia (hemoglobin levels: 13.25 ± 1.44 vs. 12.97 ± 
± 1.44 mg/dL, p = 0.08) and renal diseases (Fig. 3) 
between the female patients from Germany and 
those from SE Europe.
However, despite similar rates of previously 
known renal diseases (diagnosed and treated by 
nephrologists), we found significant differences in 
creatinine values (Germany: 83.74 ± 28.93 µmol/L 
vs. SE Europe: 95.37 ± 34.2 µmol/L, p < 0.001) 
and concurrent glomerular filtration rate (GFR) cal-
culated with Modification of Diet in Renal Disease 
formula (Germany: 68.22 ± 26.88 mL/min vs. SE 
Europe: 57.98 ± 20.63 mL/min, p < 0.001) [11].
Women from Germany more frequently had 
the chronic obstructive pulmonary disease (COPD) 
(10.1% vs. 2.4%, c2 = 8.5, p < 0.01), depression 
(18.9% vs. 4.1%, c2 = 17.75, p < 0.001) and malig-
nant diseases (13.8% vs. 1.2%, p < 0.0001).
Socio-economic characteristics  
and the use of medical services
There was a considerable diversity regarding 
patients’ level of education, but in general, those 
from Germany had a higher education level. More 
patients from SE Europe reported not having any 
education (14.1% vs. 4.2%, p < 0.001). There 
were significantly more patients with only primary 
education in Germany (32.5% vs. 19.5%, p < 0.01), 
while more patients from SE Europe reported ha-
ving finished the secondary school (28.9% vs. 15%, 
p < 0.01). Twenty-six German patients and only 
6 from SE Europe had university degrees (p < 0.001).
Women from SE Europe more frequently visi-
ted the cardiologist during 1 year (Table 2).
Heart failure therapy and  
concomitant medication
Significant differences were noted in the HF 
therapy in the observed patients (Table 3). Prior 
to the inclusion in the study more women from 
SE Europe were taking beta-blockers (66.3% 
vs. 40.3%, p < 0.001). Similar results for beta-
-blocker therapy were observed for the subgroup 
of patients with the diastolic dysfunction (SE 
Europe and Germany: 76.9% vs. 37.7%). There 
were also differences in the type of the prescri-
bed beta-blocker. Female patients from Germany 
most frequently used the selective beta1 receptor 
blocker metoprolol 51.6%, while women from 
SE Europe were prescribed most frequently 
the nonselective beta/alpha1 blocker carvedilol 
39.6% (p < 0.001).
Patients from SE Europe more frequently had 
angiotensin converting enzyme (ACE) inhibitors, 
acetylsalicylic acid, organic nitrates, oral anticoa-
gulants, antiarrhythmic agents and loop diuretics 
and less frequently angiotensin receptor blockers 
(ARB), mineralocorticoid receptor antagonists 
(MRAs), antidepressants and allopurinol. No diffe-
rence was observed regarding the device and sur-
gical therapy for cardiovascular diseases (Table 4).
Figure 3. Co-morbidities in female German and patients 
from Southeastern Europe.
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Table 3. Therapy in patients from Germany and Southeastern (SE) Europe.
Drug Germany  
patients  
(n = 159)
SE Europe  
patients  
(n = 169)
P Germany 
patients with 
HFpEF  
(n = 114)
SE Europe 
with HFpEF  
(n = 55)
P
ACEI/ARB 50.9% 85.2% NS 29.8% 3.8% < 0.05
Loop diuretics 27% 46.7% < 0.001 23.7% 19.2% NS
Thiazide diuretics 33.3% 27.8% NS 38.6% 53.8% NS
Mineralocorticoid receptor  
antagonists
36.1% 6.9% < 0.001 1.8% 15.4% < 0.05
Digitalis 7.5% 10.1% NS 2.6% 7.7% NS
Organic nitrates 6.9% 39.1% < 0.001 6.1% 23.1% < 0.05
Calcium channel blockers 18.4% 23.7% NS 21.2% 46.2% < 0.05
Antiarrhythmics 0.6% 11.2% < 0.001 0.9% 3.8% NS
Statins 28.9% 39.1% 0.053 26.3% 30.8% NS
Other lipid lowering agents 1.3% 1.2% NS 1.8% 0% NS
Acetylsalicylic acid 41.5% 68.6% < 0.001 36.8% 65.4% < 0.001
Other antiplatelet therapy 5.7% 5.3% NS 1.5% 0% NS
Oral anticoagulants —  
vitamin K antagonists
10.1% 18.9% < 0.05 7% 7.7% NS
Other oral anticoagulants 1.3% 1.8% NS 0.9% 0.0% NS
Antidepressants 7.5% 1.2% < 0.01 7% 3.8% NS
Allopurinol 6.9% 0.0% < 0.001 78.6% 0.0% < 0.001
ACEI — angiotensin converting enzyme inhibitors; ARB — angiotensin receptor blockers; HFpEF — heart failure with preserved ejection fraction
Table 2. Number of contacts with health care professionals in patients from Germany and  
Southeastern (SE) Europe.
Number of contact with health care  
professionals during 1 year
Patients from  
Germany
Patients from  
SE Europe
P
Number of visits to cardiologist  
during 1 year
2.9 ± 1.9 0.67 ± 1.2 < 0.001
Number of visits to primary care physician 
during 1 year
6.2 ± 5.9 6.67 ± 4.2 0.409
Number of hospitalizations during 1 year 
due to worsening heart failure
0.31 ± 0.73 0.44 ± 0.63 0.951
Number of hospitalizations in rehabilitation 
facilities during 1 year due to heart failure
0.06 ± 0.25 0.06 ± 0.28 0.82
Table 4. Device therapy or cardiovascular surgery in patients from Germany and Southeastern (SE) 
Europe.
Device or surgical therapy Germany patients  
(n = 159)
SE Europe patients  
(n = 169)
P
Valvular replacement 3.1% 3.6% NS
Coronary artery bypass graft 3.1% 8.9% 0.058
Percutaneous coronary intervention 11.3% 5.9% NS
Pacemaker 4.4% 3% NS
Cardiac resynchronization therapy 1.3% 0% NS
Implantable cardioverter-defibrillator 0.6% 0% NS
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Discussion
Female population was underrepresented in 
SE Europe considering that in both regions patients 
were recruited in consecutive order during their 
regular visits to a cardiologist.
Our results showed marked differences in the 
etiology and treatment of HF in elderly female 
population from different parts of Europe.
In Germany, arterial hypertension was the 
most common cause of HF in women, while in 
SE Europe it was the coronary heart disease 
(CHD). No regional differences in the prevalence 
of arterial hypertension were found in this study 
(but it was more severe in female patients from 
Germany), although the data from the EVEREST 
study suggest that it is more prevalent in Eastern 
Europe [12].
Women from SE Europe develop HF earlier 
than German women, which could be attributed 
to coronary events which occurred at the younger 
age [5]. These results are in accordance with the 
higher rates of MI in Eastern Europe reported in 
a series of studies, where it was attributed partly 
to socioeconomic factors — lower education in wo-
men and lower income, emotional stress, unhealthy 
dietary style, and less physical activity as the most 
prominent but not all the factors [13]. The rates of 
MI in women correlate closely with the reported 
rates in men in different parts of Europe, suggest-
ing also that the environmental and lifestyle factors 
have significant influence on CHD development 
beside the “traditional risk factors” — genetics 
and gender [14].
Our female patients had similar cardiovascular 
risk factors with several key differences. In contrast 
to the previously published data that smoking-related 
mortality is higher in Eastern European countries 
[15], we found no significant regional differences in 
tobacco use. This could be attributed to the fact that 
we observed only elderly female population. German 
patients more frequently consumed alcohol but mo-
derately (1 drink per week), which is consistent with 
previous studies of alcohol consumption in women 
with higher education and socio-economic status. 
Furthermore, moderate alcohol intake may have 
a protective effect against CHD [16, 17].
German patients had a higher average BMI and 
were more frequently diagnosed with hyperurice-
mia. Recent data indicate, however, that Eastern 
European countries have the highest obesity preva-
lence rates for both genders, which is explained by 
a transition in the social, economic, and nutritional 
environments followed by the delayed effect of the 
Western lifestyle in the countries of the former 
“Eastern Bloc” [18–20].
Differences in BMI seen in this study could be 
due to HF duration, because HF has inflammatory 
components and leads to a progressive weight loss 
over time. The females from SE Europe had a longer 
history of HF and hence they had more complica-
tions of the disease itself, including the weight loss.
In SE Europe patients NT-proBNP levels were 
higher. Because measurements of NT-proBNP 
levels are useful in both diagnosis and prognosis 
in patients with chronic HF [21], this finding could 
suggest either more clinically severe HF or the 
undertreatment with poorer subsequent prognoses 
in SE Europe patients.
HF patients usually have 1 or more comorbidi-
ties, which are complications of HF or the combina-
tion of HF, its underlying etiology and advanced age 
[22]. Similarly, our patients had a high prevalence 
of anemia and diabetes. However, there was no sig-
nificant differences between the regions. Previous 
studies reported higher prevalence of chronic kidney 
diseases in Western Europe [12], although in our 
study patients from SE Europe had lower GFR, which 
could be attributed to longer disease duration, more 
severe forms of HF in those patients and, possibly, 
the applied therapy. Interestingly, higher NT-proBNP 
levels could be attributed not only to lower LVEF but 
also to the lower GFR in SE Europe patients [23].
As previously described, we also found regio-
nal differences in the prevalence of COPD [12]. 
German patients had more frequently COPD, 
which could be attributed in our study population 
to more frequent obesity in these patients [24]. 
Primary pulmonary hypertension was rare, while 
secondary pulmonary hypertension is a common 
feature of HF and it is associated with high morbi-
dity and mortality [25, 26].
The patients from SE Europe more frequently had 
atrial fibrillation, which could be attributed to a higher 
prevalence of HFrEF and valvular disease [27].
The female patients from Germany more fre-
quently had malignant diseases, which are more 
prevalent in developed, high income countries; 
regional variation has been attributed to different li-
festyle and environmental factors [28]. In our study, 
females from SE Europe had less frequent depres-
sion and less frequently took antidepressants than 
those living in Germany, which is not in accordance 
with previous publications [29].
We found marked differences in the socioeco-
nomic composition of the German and SE European 
study populations, which could have relevant impact 
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on health care use and outcomes. Although most 
health professionals may see CHD merely as 
a problem of the individual, socioeconomic factors 
are key determinants of CHD and its related risk 
factors. Both health care and schooling are in the 
group of socioeconomic factors, which could act 
next to the traditional risk factors [14]. While the 
control of traditional risk factors is not incompa-
tible with strategies at the societal level, in order 
to effectively reduce cardiovascular mortality in 
both developed and developing societies, a broa-
der socioeconomic approach is needed. German 
participants were more likely to have a university 
degree. Also, the pension system in Western Euro-
pe provides significantly higher monthly payment 
than those from SE Europe. More frequent visits 
to cardiologists in SE European countries could be 
ascribed to a more direct contact, which does not 
require always a referral from the patient’s primary 
care physician.
Different drugs were used in the observed 
groups of patients, which is in accordance with 
previous trials, in which different therapeutic 
approaches in HFpEF and HFrEF were investi-
gated [30]. Since patients from SE Europe more 
frequently had CHD, they more frequently used 
organic nitrates, antiarrhythmics, platelet aggre-
gation inhibitors and anticoagulant therapy. Loop 
diuretics were more frequently used in patients 
with HFrEF from SE Europe, as well as ACE 
inhibitors (in both HFrEF and HFpEF patients). 
German patients more frequently used ARBs. 
Although digitalis is used to manage symptoms 
of HF it was not used more frequently in patients 
with HFrEF. In German patients MRAs were more 
frequently used, however in the subgroup of SE 
Europe patients with HFpEF those drugs were 
more frequently prescribed. More women from SE 
Europe were taking beta-blockers prior to inclusion 
in the study, which could be attributed to a higher 
rate of coronary artery disease in SE Europe. 
Similar results were observed for the subgroup 
of patients with the diastolic dysfunction. There 
were also differences in the type of prescribed 
beta-blocker. Female patients from Germany most 
frequently took the selective beta1 receptor blocker 
which could be attributed to more frequent COPD.
Limitations of the study
All patients took part in a controlled, randomi-
zed trial with strict inclusion and exclusion criteria 
and different recruitment methods, therefore obtai-
ned results are not representative of the German 
and SE European population.
Conclusions
We found significant regional differences in 
female HF patients regarding the etiology, comor-
bidities and treatment. No significant differences 
were observed in the prevalence of traditional 
cardiovascular risk factors (hypertension, diabetes, 
hypercholesterolemia, smoking and family history 
of MI). Female population from SE Europe was 
underrepresented (29% of all participants) in com-
parison to those from Germany (54% of the study 
population). Taking into the consideration that this 
was a trial with strict inclusion/exclusion criteria, 
and our recruitment method was similar we could 
speculate that females from SE Europe could have 
less frequent HF, under-diagnosed HF, higher mor-
tality from CHD and less odds to develop HF, but the 
end-result is decisively the same — female patients 
from SE Europe were underrepresented in the trial.
The current guidelines on HF from ESC and 
other cardiology societies do not include specific 
gender-related issues, except in the case of pre-
gnancy. No regional differences are even considered. 
All the mentioned differences should be considered 
in the design and implementation of future clinical 
trials, especially as women have been underrepre-
sented in large trial populations for the past few 
decades. Furthermore, not only the women but 
elderly have often been either excluded or under-
represented in cardiovascular trials, and as such 
the evidence base is rather unsatisfactorily drawn 
either from the observational cohorts or from small 
numbers within larger randomized trials.
There is a need that cardiovascular trials 
incorporate sufficient number of patients with 
different gender, age, and ethnicity to provide 
better insights in disease etiopathology, diagnosis 
and treatment.
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